[{"id":"aa0ea678-0fd7-41d5-9cac-558568133e0c","acronym":"EBVision","url":"https://clinicaltrials.gov/study/NCT04554914","created_at":"2021-01-18T21:46:31.475Z","updated_at":"2025-02-25T15:11:41.557Z","phase":"Phase 2","brief_title":"A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases","source_id_and_acronym":"NCT04554914 - EBVision","lead_sponsor":"Atara Biotherapeutics","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tab-cel (tabelecleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-13"},{"id":"ed857d81-c1db-430d-8754-fe70af84d781","acronym":"STRASS 2","url":"https://clinicaltrials.gov/study/NCT04031677","created_at":"2021-01-18T19:47:11.156Z","updated_at":"2025-02-25T17:24:14.778Z","phase":"Phase 3","brief_title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","source_id_and_acronym":"NCT04031677 - STRASS 2","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 04/21/2027","primary_completion_date":" 04/21/2027","study_txt":" Completion: 04/21/2028","study_completion_date":" 04/21/2028","last_update_posted":"2025-01-31"},{"id":"9059f5a8-2395-4548-8c8d-e5dd82620a3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836571","created_at":"2023-11-13T21:15:12.751Z","updated_at":"2024-07-02T16:34:37.937Z","phase":"Phase 2","brief_title":"Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People \u003e= 18 Years Old With Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT05836571","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD68","pipe":"","alterations":" ","tags":["TMB • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 66","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2024-06-05"},{"id":"bcad0e5d-8e9a-4e78-8773-942d97532535","acronym":"FUCHSia","url":"https://clinicaltrials.gov/study/NCT03926936","created_at":"2021-01-18T19:20:57.374Z","updated_at":"2024-07-02T16:35:00.857Z","phase":"Phase 2","brief_title":"FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study","source_id_and_acronym":"NCT03926936 - FUCHSia","lead_sponsor":"Frederic Amant","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 12/27/2022","study_completion_date":" 12/27/2022","last_update_posted":"2024-05-27"},{"id":"ceb4a15f-4948-45ce-a9b8-6d200e3c444c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02428192","created_at":"2021-01-18T11:37:00.299Z","updated_at":"2024-07-02T16:35:12.021Z","phase":"Phase 2","brief_title":"Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma","source_id_and_acronym":"NCT02428192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/22/2015","start_date":" 04/22/2015","primary_txt":" Primary completion: 09/20/2018","primary_completion_date":" 09/20/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-04-02"},{"id":"f6e94490-8464-4ca1-871d-9dfc5c85f532","acronym":"DAPPER","url":"https://clinicaltrials.gov/study/NCT03851614","created_at":"2021-01-18T19:00:33.382Z","updated_at":"2025-02-25T15:08:21.640Z","phase":"Phase 2","brief_title":"Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03851614 - DAPPER","lead_sponsor":"University Health Network, Toronto","biomarkers":" HRD • CD4","pipe":"","alterations":" ","tags":["HRD • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 04/08/2019","start_date":" 04/08/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-15"},{"id":"cb96adf5-8ef2-4aba-9494-0926838dbfe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923778","created_at":"2023-12-07T00:15:50.855Z","updated_at":"2024-07-02T16:35:16.265Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery","source_id_and_acronym":"NCT02923778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"d24439cc-d62c-48da-9580-3c9daa1b29b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05649956","created_at":"2022-12-14T14:58:11.091Z","updated_at":"2024-07-02T16:35:18.156Z","phase":"Phase 2","brief_title":"Letrozole in Uterine Leiomyosarcoma","source_id_and_acronym":"NCT05649956","lead_sponsor":"GOG Foundation","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-02-22"},{"id":"4f2312eb-796b-4bc0-b672-f5373ded6b38","acronym":"","url":"https://clinicaltrials.gov/study/NCT05094804","created_at":"2021-10-26T20:53:14.264Z","updated_at":"2024-07-02T16:35:30.540Z","phase":"Phase 1/2","brief_title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","source_id_and_acronym":"NCT05094804","lead_sponsor":"OncoResponse, Inc.","biomarkers":" EGFR • PD-L1 • BRAF • ALK • NTRK","pipe":" | ","alterations":" EGFR mutation • BRCA mutation","tags":["EGFR • PD-L1 • BRAF • ALK • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • docetaxel • Libtayo (cemiplimab-rwlc) • OR2805"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 08/15/2024","study_completion_date":" 08/15/2024","last_update_posted":"2023-11-02"},{"id":"8dffbd9d-b6f2-4682-a5ca-cd6146347859","acronym":"TARSARC","url":"https://clinicaltrials.gov/study/NCT04807816","created_at":"2021-03-19T15:59:15.779Z","updated_at":"2025-02-25T16:11:16.285Z","phase":"Phase 2","brief_title":"Targeting ATR in Soft-tissue Sarcomas","source_id_and_acronym":"NCT04807816 - TARSARC","lead_sponsor":"Institut Bergonié","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • berzosertib (M6620)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-09-28"},{"id":"2f53be06-79ab-4bcb-95d3-0cca269af9ef","acronym":"NCI-2021-12582","url":"https://clinicaltrials.gov/study/NCT05174455","created_at":"2021-12-30T14:55:55.326Z","updated_at":"2024-07-02T16:35:36.720Z","phase":"Phase 2","brief_title":"Niraparib for the Treatment of Leiomyosarcoma","source_id_and_acronym":"NCT05174455 - NCI-2021-12582","lead_sponsor":"David Liebner, MD","biomarkers":" BRCA1 • BRCA2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-18"},{"id":"640b8ea4-dbbe-4ef7-aaf3-6fff167a55c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009201","created_at":"2021-01-18T14:48:19.930Z","updated_at":"2025-02-25T15:53:37.006Z","phase":"Phase 1b","brief_title":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03009201","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 10/08/2019","primary_completion_date":" 10/08/2019","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-08-16"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"985dbe59-edc4-40c6-b4c4-daf7da0b5372","acronym":"TRASTS","url":"https://clinicaltrials.gov/study/NCT02275286","created_at":"2022-06-01T12:55:54.963Z","updated_at":"2024-07-02T16:35:46.759Z","phase":"Phase 1/2","brief_title":"Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients","source_id_and_acronym":"NCT02275286 - TRASTS","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" FAS","pipe":"","alterations":" ","tags":["FAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2023-05-31"},{"id":"9c287f66-8773-4060-b201-60ea917c26d4","acronym":"GEMMK","url":"https://clinicaltrials.gov/study/NCT03123276","created_at":"2021-01-18T15:23:24.090Z","updated_at":"2025-02-25T16:06:04.944Z","phase":"Phase 1/2","brief_title":"Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma","source_id_and_acronym":"NCT03123276 - GEMMK","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" PD-L1 • CD8 • PD-1 • PTPRC • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • PD-1 • PTPRC • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/29/2017","start_date":" 11/29/2017","primary_txt":" Primary completion: 02/05/2023","primary_completion_date":" 02/05/2023","study_txt":" Completion: 02/05/2023","study_completion_date":" 02/05/2023","last_update_posted":"2021-06-30"},{"id":"1143e6ad-4fb3-4eac-a9d3-83858e654c43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01614795","created_at":"2021-01-18T06:55:05.325Z","updated_at":"2024-07-02T16:37:04.745Z","phase":"Phase 2","brief_title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","source_id_and_acronym":"NCT01614795","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR • IR","pipe":"","alterations":" ","tags":["mTOR • IR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/18/2012","start_date":" 06/18/2012","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2018-12-11"},{"id":"9e07322c-b2f5-4d6e-a442-18155df7e8cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00856050","created_at":"2021-01-18T03:15:42.485Z","updated_at":"2025-02-25T15:49:57.095Z","phase":"Phase 2","brief_title":"Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma","source_id_and_acronym":"NCT00856050","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2017-04-18"}]